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Benign biliary strictures can be attributable to a large variety of causes, but are commonly iatrogenic after direct or vascular injury during laparoscopic
cholecystectomy and other biliary procedures. An increasing number of patients present with strictures of bilioenteric anastomoses after liver trans-
plantation and radical surgery for hepatopancreaticobiliary cancer. Endoscopic access to the biliary tree may be difﬁcult or impossible following pan-
creaticoduodenectomy, and in this context strictures are best approached percutaneously. In the past, strictures could only be managed with repeated
balloon dilatations and/or long-term transhepatic catheter placement. This is not very satisfactory from a patient point of view. A long-term external drain
is disﬁguring and challenging to manage, and the patient has to undergo repeated, potentially very painful procedures. Newer developments attempting
to achieve long-term resolution of benign strictures include fully covered, removable metal stents and the emerging option of biodegradable stents. Early
outcomes of these new technologies are promising, but require a careful and considered multidisciplinary approach and heavy clinical involvement of the
interventional radiologist.
Copyright  2015, Society of Gastrointestinal Intervention. Published by Elsevier.
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There are many causes of benign strictures of the biliary tree,
which include inﬂammation, gall stone disease, infection including
parasites, and congenital abnormalities,1 with iatrogenic strictures
becoming more prevalent.
During cholecystectomy, strictures may be caused by direct
trauma to the bile duct, thermal injury from cauterization, ischemia
due to vascular injury, or occlusion by erroneous application of
vascular clips. An increasingly important context is the radical
treatment of cancers of the bile duct, pancreas, or duodenum.
Although surgical revision is still regarded as a gold standard of
treatment, this may be undesirable after radical cancer surgery, and
patients increasingly expect to be treated with a minimally invasive
approach.
Strictures of the anastomosis following pancreaticoduodenec-
tomy are particularly difﬁcult to manage because endoscopic access
may not be possible even with balloon enteroscopy or endoscopic
ultrasound. The same applies to liver transplantation, where there
is an additional risk of developing ischemic biliary strictures owing
to the devascularization.
Benign bile duct strictures carry the risk of stone formation and
ascending cholangitis, which in itself may be life-threatening but
can also lead to subsequent biliary cirrhosis.2 Dealing with benign
bile duct strictures can be extremely challenging and requires good
collaborationwithin the multidisciplinary team in order to give the1Department of Radiology, Asan Medical Centre, Seoul, Korea
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cholangiography allows drainage of an infected system and estab-
lishes access for repeat procedures.3 However, this requires inser-
tion of a transhepatic catheter, which is uncomfortable for the
patient and very inconvenient in terms of the external drainage.
Interventional endoscopic ultrasound is a rapidly developing
ﬁeld, causingmuch excitement among endoscopists. Unfortunately,
in an attempt to push the boundaries, aggressive transesophageal
and transgastric access is often promoted as “the new way,” when
collaboration with the radiologist might allow a much safer com-
bined approach.4 A guidewire placed percutaneously into the du-
odenum can be retrieved endoscopically, allowing a much more
physiological drainage arrangement than with an extra-anatomical
puncture (Fig. 1).
Owing to the high rate of recurrence of benign strictures, repeat
procedures are usually required. A percutaneous approach allows
access to be maintained and is often the most appropriate man-
agement. Specialist teams need to be aware of the options provided
by radiological methods, and only close integration of the spe-
cialties can give patients the best chance of a successful outcome.
Preparation
High-quality imaging is essential in the workup of the patient in
order to conﬁrm the benign nature of the lesion as well as the most
appropriate access route. Baseline investigations should include, Wilmslow Road, Manchester M20 4BX, UK.
vier. Open access under CC BY-NC-ND license.
Fig. 1. Combined procedure following failed interventional endoscopy for a distal common bile duct (CBD) stricture. (A) After an unsuccessful attempt at endoscopic retrograde
cholangiopancreatography (ERCP), EUS-guided transduodenal puncture managed to opacify the bile duct, but failed to achieve access into the CBD. Arrow: bile duct stone. (B) An 8F
internal–external drain (arrowheads) was inserted percutaneously with the lower end in the fourth part of the duodenum. (C) After resolution of sepsis, retrograde access was
obtained alongside the drain, followed by, stricture dilatation and sphincteroplasty with a 12  40 mm balloon (arrowheads) and the stone crushed.
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presence of ascites and the signs of cirrhosis and portal venous
hypertension. Computed tomography is usually the mainstay for
planning, but magnetic resonance has a number of advantages. The
biliary anatomy is very well demonstrated by magnetic resonance
cholangiopancreatography, whichdwith added sequencesdalso
allows characterization of the lesion to be treated.
A full biochemical proﬁle, full blood count, and clotting screen
are mandatory. Coagulopathy is usually corrected within 24 hours
with an intravenous administration of 5–10mg vitamin K, if there is
sufﬁcient hepatocellular function.5
Signiﬁcant amounts of ascites separating the liver from the
abdominal wall should be drained prior to biliary intervention as
this increases the risk of hemorrhage and catheter displacement
into the peritoneum.
It needs to be understood that chronic biliary obstruction
particularly associated with low-grade sepsis may render the liver
parenchyma too stiff to allow dilatation of the bile ducts, even in
complete obstruction. Occasionally, this may even be associated
with a normal bilirubin, but usually with a markedly raised alkaline
phosphatase.
Gas in the bile ducts may reﬂect infection with gas-forming
organisms, such as yeasts, and be mistaken as a sign of a patent
connection with the small bowel. Administration of prophylactic
antibiotics is not always required but should be intravenously
administered for at least 24 hours if there is any suggestion of
biliary sepsis. Secure intravenous access, ideally in both arms, must
be established prior to the procedure and appropriate ﬂuid resus-
citation performed.
Planning of the puncture site needs to take into account the
biliary anatomy and location of the stricture, but also potentially
further steps that might be required in the future, such as insertion
of long-term catheter or subsequent stent removal.
The technique of percutaneous transhepatic cholangiography is
well established. In a nutshell, it involves ultrasound guided
puncturewith a 21–22G Chiba needle into a suitable duct, insertion
of a 0.018-inch guidewire, overwhich a 6F access system is inserted.
This will accept a 0.035-inch guidewire, at which point a simple
external drain can be inserted or the access upgraded to allow for
therapeutic maneuvers.
8F vascular access sheaths (Fig. 2A) are ideal for procedures
where a number of different tools such as catheters, dilatation
balloons, stents, and drains may have to be passed. They safeguard
the access into the biliary tree and protect the transhepatic trackfrom the trauma of multiple exchanges. The side arm allows
contrast injection without having to remove the catheter or the
guidewire, and a radio opaque ring marker at the tip reduces error
regarding the position in the duct and during stent deployment.
Sheaths allow operators to work with a 6F catheter along a safety
wire (Fig. 2B) and are large enough to accommodate most standard
stent delivery systems. If larger transhepatic tracks are required,
gradual and gentle dilatation over ultrastiff wires may achieve this.
Biliary intervention, particularly dilatation, can be exquisitely
painful and requires at the very least expert administration of
conscious sedation. Electroencephalography guidance improves
the accuracy of the sedation level,6 but many of these cases are
better performed under deep propofol sedation or general
anesthesia.
Balloon dilatation
Pneumatic dilatation of the stricture is easily performed with an
angioplasty balloon in most cases. It is desirable to achieve a 10-
mm diameter, but this may require multiple attempts. Angio-
plasty balloons vary substantially in their rated dilatation pressure
as well as their maximum burst pressure. It is advisable to use a
pressure inﬂator with an attached manometer, as it allows much
more controlled inﬂation of the balloon as well as much higher
inﬂation pressures than hand inﬂation. Tough biliary strictures may
need dilatation pressures well in excess of 10 atm and even high-
pressure balloons occasionally rupture during a procedure. This
should be avoided. Torn balloons may cause signiﬁcant trauma
during removal through the transhepatic track but can usually be
extracted through a transhepatic sheath without too much difﬁ-
culty. It is worth noting that smaller balloons (e.g. 6–8 mm) tend to
have higher burst pressures andmay perform better than 10- or 12-
mm balloons.
There is no consensus on how long dilatation balloons should be
left inﬂated. One school of thought is that once the stricture is
disrupted, the job is done. However, strictures vary considerably in
their response, and more complex strictures may beneﬁt from
leaving the balloon inﬂated for several minutes.
Cutting balloons incorporating little metal blades are available
for angioplasty of calciﬁed arteries. These cause a linear incision
within the endothelium, are supposed to achieve a more deﬁnitive
dilatation, and result in subsequent linear rather than recurrent
circumferential scarring. Their use within the bile duct has been
described,7,8 but their value remains to be established.
Fig. 2. Sheath used for transhepatic access. (A) “Radiofocus” vascular access sheath (Terumo, Bagshot, UK) with radiopaque marker (arrow). The side arm allows contrast injection
with a catheter and guidewire in situ. (B) “Safety-wire” technique: The working biliary catheter (arrow) is inserted alongside an additional wire placed across the lesion (arrowhead),
to allow rapid “bail-out” insertion of a drain in case of unexpected developments.
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long-term remodeling and prevent restenosis. Therefore, it is
generally accepted that large drains should be placed across the
stricture following dilatation. These need to be left for 4–6 weeks,
which unfortunately has a serious impact on the patient’s daily life
and often causes signiﬁcant pain as the liver moves with breathing,
laughing, coughing, and hiccups. Softer catheters with a skin-level
external hub are easier to manage and less painful than conven-
tional polyurethane pigtail drains (Fig. 3). They also prevent skin
exposure to bile, which causes skin excoriation and wound break-
down if a skin-level bag is used (Fig. 4).Mechanical dilatation
Good results can be achieved by inserting increasing numbers of
plastic stents during endoscopic retrograde cholangiopancreatog-
raphy,9 and this is probably the method of choice where the stric-
ture is accessible endoscopically. This is not a practical option for
percutaneous management. Conventional transhepatic drains
range from 6F to 10F (2–3.3 mm). It is not feasible to insert three or
four of these side by side as with endoscopic plastic stents. How-
ever, if a 10F or a 12F drain can achieve a permanent 3–4-mm
diameter of the bile duct, this might result in an acceptable
outcome.
A few transhepatic systems are available for placing straight
plastic biliary stents percutaneously, and theoretically several of
these could be placed alongside each other. However, percutaneousFig. 3. Low proﬁle internal–external “Munich” biliary drain (Peter Pﬂugbeil GmbH, München
extension (arrow) for combined internal and external drainage (bottom insert).removal or displacement of these into the bowel below is virtually
impossible, and this should not be considered as a treatment option
in patients with a good long-term prognosis.Self-expanding metal stents
Because of the speciﬁc properties of the alloy, which are
described in detail elsewhere,10 nitinol stents achieve better long-
term results in stricture dilatation than plastic stents11 or balloon
dilatation.12 As a principle, only fully covered metal stents should
be inserted across benign strictures in patients with a good long-
term prognosis. Bare or partially covered stents result in reactive
tissue hyperplasia growing through the interstices of the stent,
which results in occlusion and irretrievability of the stent. Salvage
maneuvers using “stent-in-stent” technology to cause pressure
necrosis of the ingrowing tissue have been described.13 However,
these are risky and should be regarded as an emergency method to
salvage unplanned situations.
An increasing number of removable, fully covered biliary stents
are available (Fig. 5). Some designs attempt to reduce migration by
varying the weave through the stent skeleton and the resulting
radial forces. In order to facilitate removal, the majority of these are
equipped with a retrieval lasso for catching with endoscopic for-
ceps. This may be performed as a simple extraction from the distal
end, which results in elongation and narrowing of the stent.
Alternatively, knitted stents can be inverted into themselves by
traction from the proximal end, as described in the esophagus.14, Germany) with clip-on cap (arrowhead) for internal drainage (top insert) or drainage
Fig. 4. Conventional 8F internal–external pigtail drain: beginning skin damage after 3
days of exposure to bile and traction on the silk skin suture.
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w75% of cases,15 and patients should be informed and their consent
sought for the consequences of failed stent removal.
Percutaneous capture of a conventional purse string is much
more difﬁcult. Stents designed for percutaneous removal are
available with a circumferential retrieval string at the proximal end.
The retrieval string projects into the stent lumen. It is capturedwith
a specially shaped hook, similar to the arresting wires on an aircraft
carrier.16Fig. 5. Removable metal stents. (A) Fully covered biliary stent for benign strictures (S&G Bio
the stent in order to reduce stent migration. Arrow: removal string. (B) Fully covered knitted
distal capture strings for conventional extraction. Arrowheads: proximal capture string for i
(TaeWoong Medical, Gyeonggi-Do, Korea). Arrow: removal string offset into the stent lumeTraction contracts the proximal end, allowing this to be pulled
into a transhepatic sheath (Fig. 6). This approach is relatively new,
but initial results are encouraging with migration rates of 17%,
successful removal in> 95% of cases, and long-term clinical success
of 86%.17
It remains to be determined how long removable stents should
be left in place. There is a minimum dwell time that should allow
the disrupted stricture to heal. If left too long, the stent can cause a
tissue reaction that impedes removal, even with fully covered
stents.18 Furthermore, no current materials have 100% bioresistance
in the hostile environment of the liver and duodenum. The metal
and membrane are exposed to bile and potentially gastric acid,
which results in degradation of the materials, and occasionally in
metal fatigue and stent fracture. A dwell period of 4–5 weeks is
currently regarded as the upper limit, although there is anecdotal
evidence that some stents may remain intact for a signiﬁcantly
longer period.
It must be remembered that a fully covered stent carries the risk
of occluding side branches of the biliary tree and the cystic and
pancreatic ducts.Biodegradable stents
In 2014, only a single biodegradable (BD) GI stent was available
on the market, fashioned from a polydioxanone (PDX) mono-
ﬁlament (Ella-CS, Hradec Kralove, Czech Republic).19 The only
licensed application of this stent is for the treatment of benign
esophageal strictures, but it has been used off-label throughout the
GI tract in benign strictures20 as well as cancer.21–23 PDX, a polymer
used widely in bioabsorbable materials such as sutures and or-
thopedic prostheses, is degraded by hydrolysis. The material
weakens after 2 months, then becomes brittle and starts to frag-
ment. Sporadic case reports exist, which describe the successfultech, Gyeonggi-Do, Korea). The weave of the stent skeleton varies through the length of
biliary “Hanaro” stents for endoscopic removal (MI Tech, Gyeonggi-Do, Korea). Arrows:
nversion of the stent. (C) Fully covered “Song” biliary stent for percutaneous extraction
n for capture with a hook.
Fig. 6. Stent removal. (A) Therapy-resistant stricture after Whipple’s procedure for pancreatic cancer. (B) Retrievable 10 mm  60 mm “Song” stent placed across the stricture. (C) At
1 week, the stent has fully expanded; internal–external drain in situ. (D) Stent removal after 2 months: percutaneous removal sheath and capture hook in place. (E) Stent extraction
into the removal sheath. (F) Cholangiography 2 weeks after stent removal shows a patent anastomosis, prior to drain removal. The patient is asymptomatic and shows no evidence
of recurrence after 82 months.
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stents (Fig. 7). These are used off-label on a named patient basis. It
must be borne in mind that PDX stents do not dissolve like sugar in
tea, but slowly disintegrate and small fragments of stent are passed
through the stricture. In cases of an intact Sphincter of Oddi below
it, this can result in biliary colic and cholangitis.26 However, they
seem an ideal choice for the treatment of strictures of bilioenteric
anastomoses, where a capacious loop of bowel is present below.
At present, the radiolucent BD stents need to be hand-loaded
into a 13F delivery system (Fig. 8), which requires signiﬁcant dila-
tation of the track in order to pass through the liver. Efforts are
being made to improve the loading mechanism and reduce the size
of the delivery system. BD stents are as yet not licensed for use in
the biliary tree and need to be used off-label on a named patient
basis.Fig. 7. An 8 mm  70 mm demonstration model of a biodegradable biliary Ella-DV
stent showing spontaneous fragmentation after 18 months of exposure to room air.Possible future developments
Other treatment strategies pursued in the esophagus include
the injection of nonsteroidal anti-inﬂammatory drugs, such as
triamcinolone. These are extremely difﬁcult to apply in the biliary
tree.
Photodynamic therapy has been applied with varying degrees of
success within malignant biliary strictures and probably has no role
to play in benign diseases.
Drug eluting stents have a local cytotoxic effect in malignant
disease and can delay the time to reocclusion. To what extent local
drug delivery can reduce the risk of restenosis has yet to be
explored, but initial case reports have identiﬁed this as a potentially
viable strategy.27
Conclusion
The percutaneous management of benign biliary strictures al-
lows the simultaneous or subsequent application of a number of
different treatment strategies. In the ﬁrst instance, simple balloon
dilatation should be attempted, followed by insertion of a large-
bore catheter. Where the technology is available, fully covered
removable metal stents may provide a better result, although the
risk of inability to remove the stent has to be discussed in detail
with the patient.
BD stents, which are likely to be available with a BD cover in the
future, may represent the best treatment strategy, as no removal
procedure is required. Potentially, thesemight incorporate immune
modulating drugs to prevent stricture reoccurrence. Owing to the
Fig. 8. Biodegradable stent placement. (A) A 10-mm Ella-DV stent with its 13F delivery system. Arrowheads: radiopaque gold markers. (B) The same stent after deployment across a
strictured choledochojejunostomy. The stent is radiolucent, but identiﬁed by the two gold markers at the ends of the stent (arrowheads). Arrow: marker on internal–external drain,
which was left for access.
Gastrointestinal Intervention 2015 4(1), 9–1414piecemeal disintegration, current BD stents have to be used with
caution above an intact sphincter, but may have a major role to play
in anastomotic strictures after biliary diversion.
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